Ensign Peak Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Ensign Peak Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,180	Closed	-$58K	–	1931
2022 Q3	$58K	Buy	7,180 +4,500	+168%	+$40.8K	﹤0.01%	2194
2022 Q2	$19K	Hold	2,680	–	–	﹤0.01%	2129
2022 Q1	$41K	Buy	2,680 +470	+21%	+$7.38K	﹤0.01%	2145
2021 Q4	$48K	Buy	+2,210	New	+$54.2K	﹤0.01%	2145

Other funds holding FDMT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Ensign Peak Advisors's FDMT Position: Q4 2022 in Review

Ensign Peak Advisors sold out of 4D Molecular Therapeutics (FDMT) in Q4 2022, closing a stake of 7,180 shares — an estimated $58K sold.

Ensign Peak Advisors first reported a position in FDMT in Q4 2021 and held it in 4 quarters. The position peaked at $58K in Q3 2022. 96 funds tracked by Wall St. Rank hold FDMT as of Q4 2022.

Ensign Peak Advisors reported no remaining 4D Molecular Therapeutics position as of Q4 2022 after selling out during the quarter.
Ensign Peak Advisors sold 7,180 4D Molecular Therapeutics shares in Q4 2022, an estimated $58K.
Ensign Peak Advisors first reported a position in 4D Molecular Therapeutics in Q4 2021 and held it in 4 quarters.
Ensign Peak Advisors's 4D Molecular Therapeutics position peaked at $58K in Q3 2022.
96 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.